top of page

Pavaka Wins Rev1 Ventures Concept Contract Award to Advance Next-Generation Dressing Development

Writer: Brent Toto
Brent Toto
Nov 24, 2025
2 min read

Updated: 3 days ago

COLUMBUS, Ohio — November 24, 2025 — Rev1 Ventures has told Pavaka Wound Care it will move forward with a Concept Contract award, pending successful completion of diligence. The non-dilutive funding will help the company advance its next-generation electroceutical dressing and strengthen its intellectual property.


Rev1's Concept Contract funding draws on the State of Ohio's Entrepreneurial Signature Program and The Ohio State University's commercialization contract funds. It is designed to help Ohio startups move university-born technologies through critical early proof-of-concept work.


Pavaka presented its plan to Rev1 on November 19, 2025. The award will support two priorities: development of a composite version of the company's investigational electroceutical dressing, and new patent filings that extend protection to next-generation designs. Both build on the platform Pavaka exclusively licenses from Ohio State, and the dressing generates a low-level electric field at the wound surface.


The award comes at a milestone moment. Pavaka completed Rev1's Customer to Capital accelerator and pitched at the program's Investor Showcase on November 20, 2025. It also builds on the Technology Validation and Start-up Fund award Pavaka received from the Ohio Department of Development in April 2025, which is supporting design-for-manufacturing work with the company's Ohio manufacturing partner.


Together, these state and university-backed programs reflect a broader commitment to turning Ohio research into Ohio companies. For Pavaka, that means advancing a technology developed at Ohio State, manufacturing it in Ohio and building a team in Columbus.


Pavaka thanks Rev1 Ventures, The Ohio State University and the State of Ohio for their continued investment in the company and in the region's medical technology ecosystem.


Because the Concept Contract is non-dilutive, it advances Pavaka's development plan without reducing founder or shareholder ownership. That matters for a medical device company with significant regulatory and manufacturing milestones still ahead.


The award adds to the support Pavaka received from Rev1 through its Concept to Customer and Customer to Capital programs during 2025.


The Concept Contract Agreement was finalized in December 2025, and work under the award began that month.


"Rev1 and Ohio State have backed Pavaka at every stage, and this award lets us push the next generation of our dressing forward while protecting the innovations that come out of that work." — Brent Toto, CEO and Co-Founder

Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.


About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.


Sources and further reading

Comments


bottom of page